You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neoadjuvant PD-L1 blockade

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC Trial in Switzerland (Durvalumab, Radiotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • NSCLC
  • Aarau, Switzerland
  • +12 more
Oct 17, 2022

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

Oral Squamous Cell Carcinoma Trial in Wuhan (Camrelizumab, Camrelizumanb plus TPF)

Active, not recruiting
  • Oral Squamous Cell Carcinoma
  • Wuhan, Hubei, China
    Hospital of Stomatology, Wuhan University
Aug 17, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Metastatic Malignancy Trial in Houston (Atezolizumab, Tiragolumab)

Not yet recruiting
  • Metastatic Malignancy
  • Houston, Texas
    M D Anderson Cancer Center
Dec 19, 2022

Merkel Cell Carcinoma Trial in Philadelphia (Pembrolizumab)

Not yet recruiting
  • Merkel Cell Carcinoma
  • Philadelphia, Pennsylvania
    Penn Medicine
Aug 9, 2022

Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

Recruiting
  • Rectal Neoplasms
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 25, 2023

Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy Trial in Guangzhou

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital
    Jul 27, 2023

    PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging

    Completed
    • Non-small Cell Lung Cancer (NSCLC)
      • Nîmes, France
        Jean-Paul BEREGI
      Jan 25, 2023

      MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

      Not yet recruiting
      • MSS
      • Rectal Cancer
      • Sintilimab with Interleukin-2
      • (no location specified)
      Nov 1, 2023

      Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

      Not yet recruiting
      • Colorectal Cancer Stage IV
      • +2 more
      • (no location specified)
      Jun 19, 2022

      Oral Squamous Cell Carcinoma Trial in Wuhan (Camrelizumab plus TP, TP)

      Not yet recruiting
      • Oral Squamous Cell Carcinoma
      • Camrelizumab plus TP
      • TP
      • Wuhan, Hubei, China
        Hospital of Stomatology, Wuhan University
      Mar 22, 2023

      Oesophageal Squamous Cell Carcinoma Trial in Shanghai (PD-L1 Antibody SHR-1316)

      Recruiting
      • Oesophageal Squamous Cell Carcinoma
      • PD-L1 Antibody SHR-1316
      • Shanghai, China
        180 Fenglin Road
      Jun 12, 2022

      Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Houston (drug, behavioral, radiation)

      Not yet recruiting
      • Squamous Cell Carcinoma
      • Oral Cavity Squamous Cell Carcinoma
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 27, 2023

      Nausea With Vomiting Chemo-Induced Trial in Wuhan (Ondansetron every 3 weeks, Aprepitant, Dexamethasone)

      Not yet recruiting
      • Nausea With Vomiting Chemotherapy-Induced
      • Ondansetron every 3 weeks
      • +3 more
      • Wuhan, Hubei, China
        Hubei Cancer Hospital
      Oct 8, 2023

      Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

      Not yet recruiting
      • Multiple Cancer
      • Colorectal Cancer
      • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
      • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
      • (no location specified)
      Aug 20, 2023

      Unmethylated Glioblastoma Trial in Saint Louis (Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation

      Not yet recruiting
      • Unmethylated Glioblastoma
      • Personalized Neoantigen DNA vaccine
      • +2 more
      • Saint Louis, Missouri
        Washington University School of Medicine
      Feb 14, 2023

      Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

      Recruiting
      • Breast Cancer
      • Chidamide Plus Toripalimab Plus Paclitaxel
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Feb 19, 2023

      Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8 Trial in Atlanta

      Recruiting
      • Metastatic Non-Small Lung Cell Cancer
      • +4 more
      • Atlanta, Georgia
        Winship Cancer Institute of Emory University
      Oct 19, 2022

      Bevacizumab Combined With PD-1 Monoclonal Antibody in

      Not yet recruiting
      • Colorectal Cancer
      • Bevacizumab Combined With PD-1 Monoclonal Antibody
      • (no location specified)
      Nov 8, 2023

      Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

      Active, not recruiting
      • Gastric or Gastroesophageal Junction Adenocarcinoma
      • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
      • Nanjing, Jiangsu, China
        Jiangsu Cancer Hospital
      Jul 4, 2023

      NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

      Recruiting
      • NSCLC
      • NK510
      • Tislelizumab，atezolizumab or sugemalimab
      • Nanjing, Jiangsu, China
        General Hospital of Eastern Theater Command
      Oct 23, 2023

      Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

      Not yet recruiting
      • Lung Cancer
      • Centipeda minima+PD-1/PD-L1 inhibitor
      • PD-1/PD-L1 inhibitor
      • (no location specified)
      Feb 17, 2023

      Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, Tremelimumab (Cohort A

      Recruiting
      • Intermediate Stage of Hepatocellular Carcinoma
      • Hepatocellular Carcinoma
      • Baltimore, Maryland
        Sidney Kimmel Comprehensive Cancer Center
      Oct 6, 2022

      Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

      Not yet recruiting
      • Colorectal Cancer
      • Serplulimab + FOLFOXIRI
      • Radiation therapy
      • (no location specified)
      Oct 24, 2023